CELLINK announces intention to carry out directed share issues of approximately 13.5% of the outstanding shares to finance the acquisition of SCIENION AG
CELLINK AB (publ) (“CELLINK” or the “Company”) hereby announces its intention to carry out directed share issues of series B shares corresponding to approximately 13.5 percent of the total number of outstanding shares in the Company (the “Share Issues”). The Share Issues will consist of newly issued series B shares corresponding to 10 percent of the total number of outstanding shares in line with the authorization granted by the extraordinary general meeting that was held on July 16, 2020 and additional series B shares corresponding to approximately 3.5 percent of the total number of